Motolimod
- Generic Name
- Motolimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H34N4O2
- CAS Number
- 926927-61-9
- Unique Ingredient Identifier
- WP6PY72ZH3
- Background
Motolimod has been used in trials studying the treatment of Lymphoma, Tongue Cancer, Ovarian Cancer, Adult Solid Neoplasm, and Fallopian Tube Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Intratumoral Microdosing of Motolimod in HNSCC
Early Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Presage Biosciences
- Target Recruit Count
- 1
- Registration Number
- NCT04272333
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Oregon Health & Science University (OHSU), Portland, Oregon, United States
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 53
- Registration Number
- NCT02431559
- Locations
- 🇺🇸
Research Facitlity, Phoenix, Arizona, United States
🇨ðŸ‡Research Facility, Lausanne, Switzerland
A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 18
- Registration Number
- NCT02124850
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath